Atezolizumab (A) plus pertuzumab/trastuzumab/hyaluronidase (PHESGO) in patients (pts) with solid tumors with ERBB2 alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study

Authors

• Timothy Lewis Cannon
• Michael Rothe
• Elizabeth Garrett-Mayer
• Andrew Gregory, Advocate Health - MidwestFollow
• Meredith McKean
• Kunal C. Kadakia
• Evan P. Pisick
• Bamidele Adesunloye
• Jasdeepa Nagi
• Erwin Grussie
• Carmen Julia Calfa
• Majd Chahin
• Jaykumar Ranchodbhai Thumar
• Stanley Madu Nwabudike
• Gahyun Gim
• Abigail Gregory
• Dominique C. Hinshaw
• Gina N. Grantham
• Susan Halabi
• Richard L. Schilsky

Recommended Citation

Cannon TL, Rothe M, Garrett-Mayer E, et al. Atezolizumab (A) plus pertuzumab/trastuzumab/hyaluronidase (PHESGO) in patients (pts) with solid tumors with ERBB2 alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Journal of Clinical Oncology. 2026/06/01 2026;44(16_suppl):2644-2644. doi:10.1200/JCO.2026.44.16_suppl.2644

Type

Abstract